Literature DB >> 33040326

The splicing regulatory factor hnRNPU is a novel transcriptional target of c-Myc in hepatocellular carcinoma.

Biao Zhang1,2, Hai-Yang Wang1,2, De-Xi Zhao3, Dong-Xing Wang1,2, Quan Zeng1,2, Jia-Fei Xi1,2, Xue Nan1,2, Li-Juan He1,2, Jun-Nian Zhou1,2,4, Xue-Tao Pei1,2, Wen Yue1,2.   

Abstract

Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality. Here, we found that hnRNPU is overexpressed in HCC tissues and is correlated with the poor prognosis of HCC patients. Besides, hnRNPU is of high significance in regulating the proliferation, apoptosis, self-renewal, and tumorigenic potential of HCC cells. Mechanismly, c-Myc regulates hnRNPU expression at the transcriptional level, and meanwhile, hnRNPU stabilizes the mRNA of c-MYC. We found that the hnRNPU and c-Myc regulatory loop exerts a synergistic effect on the proliferation and self-renewal of HCC, and promotes the HCC progression. Taken together, hnRNPU functions as a novel transcriptional target of c-Myc and promotes HCC progression, which may become a promising target for the treatment of c-Myc-driven HCC.
© 2020 Federation of European Biochemical Societies.

Entities:  

Keywords:  c-Myc; hepatocellular carcinoma; hnRNPU; regulatory loop; therapeutic target

Mesh:

Substances:

Year:  2020        PMID: 33040326     DOI: 10.1002/1873-3468.13943

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

1.  Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma.

Authors:  Youli Du; Xiaoou Ma; Dongxu Wang; Yuguang Wang; Tianyu Zhang; Lianjie Bai; Yunlong Liu; Shaosen Chen
Journal:  J Gastrointest Oncol       Date:  2021-10

2.  Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.

Authors:  Linfeng Xian; Pei Zhao; Xi Chen; Zhimin Wei; Hongxiang Ji; Jun Zhao; Wenbin Liu; Zishuai Li; Donghong Liu; Xue Han; Youwen Qian; Hui Dong; Xiong Zhou; Junyan Fan; Xiaoqiong Zhu; Jianhua Yin; Xiaojie Tan; Dongming Jiang; Hongping Yu; Guangwen Cao
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

3.  GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma.

Authors:  Zhiwei Dong; Kok Siong Yeo; Gonzalo Lopez; Cheng Zhang; Erin N Dankert Eggum; Jo Lynne Rokita; Choong Yong Ung; Taylor M Levee; Zuag Paj Her; Cassie J Howe; Xiaonan Hou; Janine H van Ree; Shuai Li; Shuning He; Ting Tao; Karen Fritchie; Jorge Torres-Mora; Julia S Lehman; Alexander Meves; Gina L Razidlo; Komal S Rathi; S John Weroha; A Thomas Look; Jan M van Deursen; Hu Li; Jennifer J Westendorf; John M Maris; Shizhen Zhu
Journal:  Cancer Res       Date:  2021-02-18       Impact factor: 13.312

4.  A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.

Authors:  Xiaozhu Tang; Zhendong Deng; Pinggang Ding; Wanting Qiang; Yue Lu; Shengyao Gao; Ye Hu; Ye Yang; Juan Du; Chunyan Gu
Journal:  J Exp Clin Cancer Res       Date:  2022-03-08

5.  Systematic Identification of the RNA-Binding Protein STAU2 as a Key Regulator of Pancreatic Adenocarcinoma.

Authors:  Xiao Wang; Wenbin Kuang; Jiayu Ding; Jiaxing Li; Minghui Ji; Weijiao Chen; Hao Shen; Zhongrui Shi; Dawei Wang; Liping Wang; Peng Yang
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

6.  Integrative Analysis Reveals the Potential Role and Prognostic Value of GOLM1 in Hepatocellular Carcinoma.

Authors:  Yan Lin; Ziqin He; Xing Gao; Lu Lu; Cheng Lu; Julu Huang; Min Luo; Jiazhou Ye; Rong Liang
Journal:  Oxid Med Cell Longev       Date:  2022-09-28       Impact factor: 7.310

7.  High expression of RUVBL1 and HNRNPU is associated with poor overall survival in stage I and II non-small cell lung cancer patients.

Authors:  Justyna Durślewicz; Jakub Jóźwicki; Anna Klimaszewska-Wiśniewska; Aleksandra Zielińska; Paulina Antosik; Dariusz Grzanka; Marcin Braun
Journal:  Discov Oncol       Date:  2022-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.